Summit Therapeutics (SMMT) Exchange Rate Effect (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Exchange Rate Effect came in at $1000.0 in Q2 2026, down 98.36% YoY from $61000.0 in Q2 2025, and up 105.26% on a QoQ basis from -$19000.0 in Q1 2026.
Summit Therapeutics (SMMT) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Exchange Rate Effect data on file, last reported at $1000.0 in Q2 2026.
- Quarterly Exchange Rate Effect fell 98.36% year-over-year to $1000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$15000.0 (down 114.29% YoY) and the FY2025 annual result came in at $102000.0, up 666.67% from the prior year.
- Exchange Rate Effect rose to $1000.0 in Q2 2026, from -$19000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $1.4 million in Q4 2022 to a low of -$1.8 million in Q3 2022.
- A 5-year average of -$17611.1 and a median of $6500.0 in 2024 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 428.16% in 2022, down 621.74% in 2022.
- Tracing SMMT's Exchange Rate Effect over 5 years: stood at $1.4 million in 2022, then plunged by 80.22% to $272000.0 in 2023, then tumbled by 139.71% to -$108000.0 in 2024, then surged by 82.41% to -$19000.0 in 2025, then jumped by 105.26% to $1000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $1000.0 (Q2 2026), -$19000.0 (Q1 2026), and -$19000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Mar 31, 2026 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Dec 31, 2024 | -108,000.00 |
| Dec 31, 2024 | -108,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Mar 31, 2024 | -36,000.00 |